Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Carlos Gomez-RocaPhilippe CassierDmitriy ZamarinJean-Pascal H MachielsJose Luis Perez GraciaF Stephen HodiAlvaro TausMaria Martinez GarciaValentina BoniJoseph P EderNavid HafezRyan J SullivanDavid McdermottStephane ChampiatSandrine AspeslaghCatherine TerretAnna-Maria JeggWolfgang JacobMichael A CannarileCarola RiesKonstanty KorskiFrancesca MichielinRandolph ChristenGalina BabitzkiCarl WatsonGeorgina Meneses-LorenteMartin WeisserDominik RüttingerJean-Pierre DelordAurélien MarabellePublished in: Journal for immunotherapy of cancer (2022)
Emactuzumab in combination with atezolizumab demonstrated a manageable safety profile with increased fatigue and skin rash over usual atezolizumab monotherapy. A considerable ORR was particularly seen in ICB-experienced NSCLC patients. Increase ofCD8 +TILs under therapy appeared to be associated with persistence of a TAM subpopulation.